SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has ...

Moleculin is currently advancing a Phase 3 clinical trial called MIRACLE, evaluating its lead program Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid ...

Moleculin Biotech Inc (NASDAQ:MBRX) saw its stock tumble 34.3% in premarket trading Thursday after announcing agreements with ...

REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug ...

Moleculin Biotech's stock crashes as a capital raise triggers fears of severe dilution, overshadowing positive Phase 3 AML trial results for Annamycin.

The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on February 20, 2026, and its existing cash and ...